Historical record - last NADAC effective date: 3/20/2024
Product Information
RIZATRIPTAN 5 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.4776 per EA under NDC 69097086585. Its NADAC has been published 384 times since Nov 23, 2016.
FDA first approved this application on Jul 1, 2013.
Strength
5 mg/1
Manufacturer
Cipla USA Inc.NDC
69097086585
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
3/20/2024
Active Ingredients
RIZATRIPTAN BENZOATEApproval Type
Generic (ANDA)
FDA Application
ANDA204339FDA Approved
7/1/2013
On Market Since
7/22/2016
Pharmacological Classes
Price Statistics
The NADAC for RIZATRIPTAN 5 MG TABLET has been published 384 times since Nov 23, 2016, and over the history we have for it it has declined 60.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4776 per EA |
|---|---|
| All-time high | $1.2127 (Dec 14, 2016) |
| All-time low | $0.4082 (Jan 18, 2023) |
| Median price | $0.7855 |
| Average price | $0.7668 |
| Largest weekly change | +49.6% (Feb 22, 2023) |
| Weeks tracked | 384 |
| Tracking since | Nov 23, 2016 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+6.5%
5Y
-43.8%
All
-60.6%
Last surveyed Mar 27, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 33% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rizatriptan Benzoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIZATRIPTAN 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RIZATRIPTAN 5 MG TABLET, manufactured by Cipla USA Inc., is $0.4776 per EA (NDC 69097086585), effective Mar 27, 2024.
How has the price of RIZATRIPTAN 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for RIZATRIPTAN 5 MG TABLET has declined 60.6%. It has been tracked across 384 weekly CMS publications since Nov 23, 2016.
What are the highest and lowest recorded NADAC prices for RIZATRIPTAN 5 MG TABLET?
Since Nov 23, 2016, the NADAC for RIZATRIPTAN 5 MG TABLET has ranged from a low of $0.4082 (Jan 18, 2023) to a high of $1.2127 (Dec 14, 2016), with a median of $0.7855 per EA.
Are there cheaper alternatives to RIZATRIPTAN 5 MG TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIZATRIPTAN 5 MG TABLET, is $0.3203 per EA — about 33% below RIZATRIPTAN 5 MG TABLET.
Who manufactures RIZATRIPTAN 5 MG TABLET?
RIZATRIPTAN 5 MG TABLET (NDC 69097086585) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.